Key technologies in oncology pipeline worldwide 2020
During 2020, the therapeutic monoclonal antibody PD-1/PD-L1 mAb had a share of 18 percent of clinical drug trials in the oncology pipeline. This statistic shows the share of clinical drug trials in the oncology pipeline worldwide in 2020, by key technology.